Mathias Lichterfeld

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2330123/publications.pdf

Version: 2024-02-01

36691 37326 134 11,206 53 100 citations h-index g-index papers 136 136 136 14726 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. Annals of Internal Medicine, 2022, 175, 95-100. | 2.0 | 36 |
| 2 | Near-Full-Length Single-Genome HIV-1 DNA Sequencing. Methods in Molecular Biology, 2022, 2407, 357-364. | 0.4 | 2 |
| 3 | Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell, 2022, 185, 266-282.e15. | 13.5 | 131 |
| 4 | Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19. Clinical Immunology, 2022, 237, 108991. | 1.4 | 36 |
| 5 | Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. Clinical Infectious Diseases, 2021, 72, 388-393. | 2.9 | 17 |
| 6 | Viral Reservoir in Early-Treated Human Immunodeficiency Virus-Infected Children and Markers for Sustained Viral Suppression. Clinical Infectious Diseases, 2021, 73, e997-e1003. | 2.9 | 11 |
| 7 | Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation. Aids, 2021, 35, 1015-1020. | 1.0 | 13 |
| 8 | Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 27 |
| 9 | Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana. Aids, 2021, 35, 2413-2421. | 1.0 | 6 |
| 10 | Functional impairment of HIV-specific CD8+ TÂcells precedes aborted spontaneous control of viremia. Immunity, 2021, 54, 2372-2384.e7. | 6.6 | 20 |
| 11 | Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo. EClinicalMedicine, 2021, 42, 101225. | 3.2 | 5 |
| 12 | Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. Science Translational Medicine, 2021, 13, eabl4097. | 5.8 | 52 |
| 13 | Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clinical Infectious Diseases, 2020, 70, 1636-1642. | 2.9 | 27 |
| 14 | Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell, 2020, 183, 143-157.e13. | 13.5 | 599 |
| 15 | Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. New England Journal of Medicine, 2020, 383, 2291-2293. | 13.9 | 1,069 |
| 16 | Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature, 2020, 585, 261-267. | 13.7 | 245 |
| 17 | Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350. | 15.2 | 96 |
| 18 | Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 235-241. | 0.9 | 12 |

| # | Article | IF | Citations |
|----|---|--------------|-----------|
| 19 | HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. Cell Reports, 2020, 33, 108502. | 2.9 | 19 |
| 20 | Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation. Nature Communications, 2020, 11, 2421. | 5.8 | 6 |
| 21 | HIV diagnostic algorithm requires confirmatory testing for initial indeterminate or positive screens in the first week of life. Aids, 2020, 34, 1029-1035. | 1.0 | 2 |
| 22 | Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies. Cell Reports, 2020, 30, 984-996.e4. | 2.9 | 22 |
| 23 | Reactivation of latent HIV moves shock-and-kill treatments forward. Nature, 2020, 578, 42-43. | 13.7 | 13 |
| 24 | Blood and Lymph Node Dissemination of Clonal Genome-Intact Human Immunodeficiency Virus 1 DNA Sequences During Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2020, 222, 655-660. | 1.9 | 24 |
| 25 | HIV-1 DNA sequence diversity and evolution during acute subtype C infection. Nature Communications, 2019, 10, 2737. | 5. 8 | 51 |
| 26 | Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. Science Translational Medicine, 2019, 11, . | 5 . 8 | 74 |
| 27 | Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. Aids, 2019, 33, 1315-1325. | 1.0 | 66 |
| 28 | Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. Journal of Clinical Investigation, 2019, 129, 988-998. | 3.9 | 209 |
| 29 | Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Is Lipopolysaccharide-Induced Inflammatory Responses. MSphere, 2018, 3, . | 1.3 | 17 |
| 30 | Pegylated Interferon-α–Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy–Treated HIV-1/Hepatitis C Virus–Coinfected Patients. Clinical Infectious Diseases, 2018, 66, 1910-1917. | 2.9 | 30 |
| 31 | Recent progress in understanding HIV reservoirs. Current Opinion in HIV and AIDS, 2018, 13, 137-142. | 1.5 | 31 |
| 32 | D-104 Clonal proliferation of CD4 T cells encoding intact HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 40-40. | 0.9 | 0 |
| 33 | Metabolic pathway activation distinguishes transcriptional signatures of CD8+ T cells from HIV-1 elite controllers. Aids, 2018, 32, 2669-2677. | 1.0 | 30 |
| 34 | Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells. Immunity, 2018, 48, 1183-1194.e5. | 6.6 | 109 |
| 35 | A Reproducibility-Based Computational Framework Identifies an Inducible, Enhanced Antiviral State in Dendritic Cells from HIV-1 Elite Controllers. Genome Biology, 2018, 19, 10. | 3.8 | 37 |
| 36 | HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. Journal of Clinical Investigation, 2018, 128, 4074-4085. | 3.9 | 67 |

| # | Article | IF | Citations |
|----|---|------|-----------|
| 37 | Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. PLoS Pathogens, 2018, 14, e1006792. | 2.1 | 74 |
| 38 | T Memory Stem Cells. , 2018, , 1963-1968. | | 0 |
| 39 | HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clinical Infectious Diseases, 2017, 64, ciw833. | 2.9 | 28 |
| 40 | T memory stem cells in health and disease. Nature Medicine, 2017, 23, 18-27. | 15.2 | 396 |
| 41 | Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2017, 64, 1686-1695. | 2.9 | 122 |
| 42 | Preferential susceptibility of Th9 and Th2 CD4+ T cells to X4-tropic HIV-1 infection. Aids, 2017, 31, 2211-2215. | 1.0 | 10 |
| 43 | HLA-G+ HIV-1-specific CD8 + T cells are associated with HIV-1 immune control. Aids, 2017, 31, 207-212. | 1.0 | 10 |
| 44 | Transcriptional Changes during Naturally Acquired Zika Virus Infection Render Dendritic Cells Highly Conducive to Viral Replication. Cell Reports, 2017, 21, 3471-3482. | 2.9 | 74 |
| 45 | Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth. JCI Insight, 2017, 2, e89574. | 2.3 | 58 |
| 46 | Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. Journal of Clinical Investigation, 2017, 127, 2689-2696. | 3.9 | 249 |
| 47 | Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. PLoS Medicine, 2017, 14, e1002461. | 3.9 | 50 |
| 48 | Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. PLoS Pathogens, 2016, 12, e1005472. | 2.1 | 77 |
| 49 | A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. PLoS Pathogens, 2016, 12, e1005545. | 2.1 | 142 |
| 50 | Follicular T helper cells: hotspots for HIV-1 persistence. Nature Medicine, 2016, 22, 711-712. | 15.2 | 10 |
| 51 | Broad activation of latent HIV-1 in vivo. Nature Communications, 2016, 7, 12731. | 5.8 | 65 |
| 52 | Diversity of HIV-1 reservoirs in CD4+ T-cell subpopulations. Current Opinion in HIV and AIDS, 2016, 11, 383-387. | 1.5 | 58 |
| 53 | Transcriptional Changes in CD8+ T Cells During Antiretroviral Therapy Intensified With Raltegravir. Open Forum Infectious Diseases, 2015, 2, ofv045. | 0.4 | 2 |
| 54 | Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers. PLoS Pathogens, 2015, 11, e1004930. | 2.1 | 77 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Second European Round Table on the Future Management of HIV. Journal of Virus Eradication, 2015, 1, 211-220. | 0.3 | 3 |
| 56 | Prolonged Antiretroviral Therapy Preserves HIV-1-Specific CD8 T Cells with Stem Cell-Like Properties. Journal of Virology, 2015, 89, 7829-7840. | 1.5 | 42 |
| 57 | T Memory Stem Cells and HIV: a Long-Term Relationship. Current HIV/AIDS Reports, 2015, 12, 33-40. | 1.1 | 52 |
| 58 | Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. Journal of Virology, 2015, 89, 10176-10189. | 1.5 | 89 |
| 59 | Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy. Journal of Virology, 2015, 89, 11284-11293. | 1.5 | 85 |
| 60 | Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain. Journal of Virus Eradication, 2015, 1, 211-20. | 0.3 | 0 |
| 61 | Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. PLoS ONE, 2014, 9, e85516. | 1.1 | 34 |
| 62 | Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4 T-Cell–Associated HIV-1 DNA in HIV-1/Hepatitis C Virus–Coinfected Patients. Journal of Infectious Diseases, 2014, 209, 1315-1320. | 1.9 | 60 |
| 63 | LILRB2 Interaction with HLA Class I Correlates with Control of HIV-1 Infection. PLoS Genetics, 2014, 10, e1004196. | 1.5 | 83 |
| 64 | Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes. PLoS Pathogens, 2014, 10, e1004287. | 2.1 | 179 |
| 65 | Dysfunctional HIV-Specific CD8+ T Cell Proliferation Is Associated with Increased Caspase-8 Activity and Mediated by Necroptosis. Immunity, 2014, 41, 1001-1012. | 6.6 | 60 |
| 66 | Studies on quantitative phosphopeptide analysis by matrixâ€assisted laser desorption/ionization mass spectrometry without label, chromatography or calibration curves. Rapid Communications in Mass Spectrometry, 2014, 28, 2681-2689. | 0.7 | 7 |
| 67 | Dendritic Cells from HIV-1 Neutralizers Efficiently Induce the Generation of CXCR5+ CXCR3+ PD1Lo CD4 T Cells with B Cell Helper Function. AIDS Research and Human Retroviruses, 2014, 30, A74-A74. | 0.5 | 0 |
| 68 | HIV-1 persistence in CD4+ T cells with stem cell–like properties. Nature Medicine, 2014, 20, 139-142. | 15.2 | 379 |
| 69 | Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase $1/2$, single group, clinical trial. Lancet HIV, the, 2014, 1, e13-e21. | 2.1 | 542 |
| 70 | Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. Journal of Virology, 2014, 88, 10056-10065. | 1.5 | 242 |
| 71 | CD4 ⁺ T-Cell Help Enhances NK Cell Function following Therapeutic HIV-1 Vaccination. Journal of Virology, 2014, 88, 8349-8354. | 1.5 | 52 |
| 72 | A Cell-Intrinsic Inhibitor of HIV-1 Reverse Transcription in CD4+ T Cells from Elite Controllers. Cell Host and Microbe, 2014, 15, 717-728. | 5.1 | 44 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Susceptibility to CD8 T-Cell–Mediated Killing Influences the Reservoir of Latently HIV-1–Infected CD4 T Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 1-9. | 0.9 | 23 |
| 74 | T Memory Stem Cells. , 2014, , 1-6. | | 0 |
| 75 | Functional Characterization of HLA-G+ Regulatory T Cells in HIV-1 Infection. PLoS Pathogens, 2013, 9, e1003140. | 2.1 | 27 |
| 76 | Acute HIV-1 Infection: A Call to Action. Annals of Internal Medicine, 2013, 159, 425. | 2.0 | 3 |
| 77 | Reactivation of latent HIV-1 in central memory CD4+T cells through TLR-1/2 stimulation. Retrovirology, 2013, 10, 119. | 0.9 | 124 |
| 78 | Antiretroviral combination therapy markedly reduces risk of heterosexual HIV-1 transmission. Evidence-Based Medicine, 2012, 17, 95-96. | 0.6 | 1 |
| 79 | Elite control of HIV: p21 (waf-1/cip-1) at its best. Cell Cycle, 2012, 11, 4097-4098. | 1.3 | 32 |
| 80 | Shelterin Dysfunction and p16 ^{INK4a} -Mediated Growth Inhibition in HIV-1-Specific CD8 T Cells. Journal of Virology, 2012, 86, 5533-5540. | 1.5 | 7 |
| 81 | Induction of Strong HIV-1–Specific CD4+ T-Cell Responses Using an HIV-1 gp120/NefTat Vaccine Adjuvanted With AS02A in Antiretroviral-Treated HIV-1–Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 1-9. | 0.9 | 16 |
| 82 | CD4 T-cell regeneration in HIV-1 elite controllers. Aids, 2012, 26, 701-706. | 1.0 | 28 |
| 83 | Systemic inhibition of myeloid dendritic cells by circulating HLA class I molecules in HIV-1 infection. Retrovirology, 2012, 9, 11. | 0.9 | 17 |
| 84 | Elite control of HIV: p21 (waf-1/cip-1) at its best. Cell Cycle, 2011, 10, 3213-3214. | 1.3 | 6 |
| 85 | Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers. Journal of Virology, 2011, 85, 3015-3019. | 1.5 | 69 |
| 86 | Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers. Journal of Virology, 2011, 85, 9646-9650. | 1.5 | 45 |
| 87 | Treating HIV-1 infection: what might the future hold?. Therapeutic Advances in Chronic Disease, 2011, 2, 293-305. | 1.1 | 4 |
| 88 | Dendritic Cell Dysfunction During Primary HIV-1 Infection. Journal of Infectious Diseases, 2011, 204, 1557-1562. | 1.9 | 36 |
| 89 | The emerging role of leukocyte immunoglobulin-like receptors (LILRs) in HIV-1 infection. Journal of Leukocyte Biology, 2011, 91, 27-33. | 1.5 | 33 |
| 90 | CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. Journal of Clinical Investigation, 2011, 121, 1549-1560. | 3.9 | 156 |

| # | Article | IF | Citations |
|-----|---|-------------|-----------|
| 91 | Epigenetic regulation of telomerase expression in HIV-1-specific CD8+ T cells. Aids, 2010, 24, 1964-1966. | 1.0 | 8 |
| 92 | Leukocyte Immunoglobulin-Like Receptors Maintain Unique Antigen-Presenting Properties of Circulating Myeloid Dendritic Cells in HIV-1-Infected Elite Controllers. Journal of Virology, 2010, 84, 9463-9471. | 1.5 | 92 |
| 93 | Soluble HLA-G Inhibits Myeloid Dendritic Cell Function in HIV-1 Infection by Interacting with Leukocyte Immunoglobulin-Like Receptor B2. Journal of Virology, 2010, 84, 10784-10791. | 1.5 | 45 |
| 94 | High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides. International Journal of Antimicrobial Agents, 2010, 35, 96. | 1.1 | 18 |
| 95 | Mutational Escape in HIV-1 CTL Epitopes Leads to Increased Binding to Inhibitory Myelomonocytic MHC Class I Receptors. PLoS ONE, 2010, 5, e15084. | 1.1 | 5 |
| 96 | HLA-B*35-Px–mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. Journal of Experimental Medicine, 2009, 206, 2959-2966. | 4.2 | 92 |
| 97 | Telomerase activity of HIV-1–specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood, 2008, 112, 3679-3687. | 0.6 | 75 |
| 98 | Recognition of a Defined Region within p24 Gag by CD8 + T Cells during Primary Human Immunodeficiency Virus Type 1 Infection in Individuals Expressing Protective HLA Class I Alleles. Journal of Virology, 2007, 81, 7725-7731. | 1.5 | 116 |
| 99 | Selective Depletion of High-Avidity Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8 + T Cells after Early HIV-1 Infection. Journal of Virology, 2007, 81, 4199-4214. | 1.5 | 109 |
| 100 | Random T-Cell Receptor Recruitment in Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8 $<$ sup>+ $<$ /sup> T Cells from Genetically Identical Twins Infected with the Same HIV-1 Strain. Journal of Virology, 2007, 81, 12666-12669. | 1.5 | 18 |
| 101 | Mutually Exclusive T-Cell Receptor Induction and Differential Susceptibility to Human Immunodeficiency Virus Type 1 Mutational Escape Associated with a Two-Amino-Acid Difference between HLA Class I Subtypes. Journal of Virology, 2007, 81, 1619-1631. | 1.5 | 75 |
| 102 | Decreased CXCR3 + CD8 T Cells in Advanced Human Immunodeficiency Virus Infection Suggest that a Homing Defect Contributes to Cytotoxic T-Lymphocyte Dysfunction. Journal of Virology, 2007, 81, 8439-8450. | 1.5 | 28 |
| 103 | A viral CTL escape mutation leading to immunoglobulin-like transcript 4–mediated functional inhibition of myelomonocytic cells. Journal of Experimental Medicine, 2007, 204, 2813-2824. | 4.2 | 95 |
| 104 | Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nature Immunology, 2006, 7, 173-178. | 7. 0 | 209 |
| 105 | T cell receptor cross-recognition of an HIV-1 CD8+ T cell epitope presented by closely related alleles from the HLA-A3 superfamily. International Immunology, 2006, 18, 1179-1188. | 1.8 | 20 |
| 106 | HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8+ T Cell Response against HIV-1. PLoS Medicine, 2006, 3, e403. | 3.9 | 273 |
| 107 | Immunological and Virological Impact of Highly Active Antiretroviral Therapy Initiated during Acute HIVâ€1 Infection. Journal of Infectious Diseases, 2006, 194, 734-739. | 1.9 | 86 |
| 108 | Loss of HIV-1-specific T cell proliferation in chronic HIV-1 infection: cause or consequence of viral replication?. Aids, 2005, 19, 1225-1227. | 1.0 | 12 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide level. Aids, 2005, 19, 1449-1456. | 1.0 | 26 |
| 110 | Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood, 2005, 106, 3366-3369. | 0.6 | 314 |
| 111 | Liver histopathology in human immunodeficiency virus-hepatitis C virus co-infected patients with fatal liver disease. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 739-745. | 1.4 | 8 |
| 112 | Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients. Journal of Infection, 2005, 50, 221-228. | 1.7 | 14 |
| 113 | Treatment of HIV-1-Associated Kaposi's Sarcoma with Pegylated Liposomal Doxorubicin and HAART Simultaneously Induces Effective Tumor Remission and CD4+ T Cell Recovery. Infection, 2005, 33, 140-147. | 2.3 | 55 |
| 114 | Limited Sequence Evolution within Persistently Targeted CD8 Epitopes in Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2005, 79, 8171-8181. | 1.5 | 41 |
| 115 | HLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load. Journal of Virology, 2005, 79, 10218-10225. | 1.5 | 68 |
| 116 | The Majority of Currently Circulating Human Immunodeficiency Virus Type 1 Clade B Viruses Fail To Prime Cytotoxic T-Lymphocyte Responses against an Otherwise Immunodominant HLA-A2-Restricted Epitope: Implications for Vaccine Design. Journal of Virology, 2005, 79, 5000-5005. | 1.5 | 39 |
| 117 | De Novo Generation of Escape Variant-Specific CD8 + T-Cell Responses following Cytotoxic T-Lymphocyte Escape in Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2005, 79, 12952-12960. | 1.5 | 122 |
| 118 | Immunodominance of HIV-1-specific CD8+ T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics. Trends in Immunology, 2005, 26, 166-171. | 2.9 | 48 |
| 119 | Selection, Transmission, and Reversion of an Antigen-Processing Cytotoxic T-Lymphocyte Escape Mutation in Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2004, 78, 7069-7078. | 1.5 | 227 |
| 120 | Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides. Journal of Virology, 2004, 78, 4463-4477. | 1.5 | 171 |
| 121 | Increased Natural Killer Cell Activity in Viremic HIV-1 Infection. Journal of Immunology, 2004, 173, 5305-5311. | 0.4 | 128 |
| 122 | Loss of HIV-1â€"specific CD8+ T Cell Proliferation after Acute HIV-1 Infection and Restoration by Vaccine-induced HIV-1â€"specific CD4+ T Cells. Journal of Experimental Medicine, 2004, 200, 701-712. | 4.2 | 314 |
| 123 | Limited Durability of Viral Control following Treated Acute HIV Infection. PLoS Medicine, 2004, 1, e36. | 3.9 | 149 |
| 124 | Differences in the Expressed HLA Class I Alleles Effect the Differential Clustering of HIV Type 1-Specific T Cell Responses in Infected Chinese and Caucasians. AIDS Research and Human Retroviruses, 2004, 20, 557-564. | 0.5 | 14 |
| 125 | Rapid Determination of the Δ32 Deletion in the Human CC-Chemokine Receptor 5 (CCR5) Gene without DNA Extraction by LightCycler Real-Time Polymerase Chain Reaction. AIDS Research and Human Retroviruses, 2004, 20, 750-754. | 0.5 | 8 |
| 126 | HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. Aids, 2004, 18, 1383-1392. | 1.0 | 99 |

| # | Article | IF | CITATION |
|-----|---|-----|----------|
| 127 | HIV-1–specific cytotoxicity is preferentially mediated by a subset of CD8+ T cells producing both interferon-γ and tumor necrosis factor–α. Blood, 2004, 104, 487-494. | 0.6 | 124 |
| 128 | The tandem-repeat polymorphism of the DC-SIGNR gene does not affect the susceptibility to HIV infection and the progression to AIDSâ ⁺ †. Clinical Immunology, 2003, 107, 55-59. | 1.4 | 29 |
| 129 | Diagnosis of Invasive Septate Mold Infections. American Journal of Clinical Pathology, 2003, 119, 854-858. | 0.4 | 208 |
| 130 | Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. American Journal of Clinical Pathology, 2003, 119, 854-8. | 0.4 | 82 |
| 131 | Reduced CC Chemokine Receptor (CCR) 1 and CCR5 Surface Expression on Peripheral Blood T Lymphocytes from Patients with Chronic Hepatitis C Infection. Journal of Infectious Diseases, 2002, 185, 1803-1807. | 1.9 | 48 |
| 132 | Antiretroviral drug toxicity – a challenge for the hepatologist?. Journal of Hepatology, 2002, 36, 283-294. | 1.8 | 115 |
| 133 | Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. Aids, 2002, 16, 2083-2085. | 1.0 | 31 |
| 134 | Mobilization of CD34+haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. British Journal of Haematology, 2000, 110, 71-81. | 1.2 | 44 |